Socio-economic Considerations in Biosafety and Biotechnology Decision Making: The Cartagena Protocol and National Biosafety Frameworks

Article 26.1 of the Cartagena Protocol on Biosafety left open the possibility for member countries to include in their biosafety regulatory processes the assessment of socio‐economic considerations. Countries may also decide to include such assessments as part of their national legislation or regula...

Full description

Saved in:
Bibliographic Details
Published in:The Review of policy research 2011-03, Vol.28 (2), p.171-195
Main Authors: Falck-Zepeda, Jose Benjamin, Zambrano, Patricia
Format: Article
Language:English
Subjects:
Agricultural biotechnology
Approval
Biosafety
Biotechnology
Cartagena Protocol on Biosafety
Decision Making
Developing countries
Environmental law, International
Environmental Policy
Genetic engineering
genetically engineered crops
Genetically modified organisms
impact assessment
Laws, regulations and rules
Legislation
Private Sector
Public safety
Public Sector
R&D
Regulation
Research & development
Safety
socio-economics
Socioeconomic factors
Technology
Treaties
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Article 26.1 of the Cartagena Protocol on Biosafety left open the possibility for member countries to include in their biosafety regulatory processes the assessment of socio‐economic considerations. Countries may also decide to include such assessments as part of their national legislation or regulations for the approval and deliberate release into the environment of genetically engineered technologies. Countries are debating if and how to implement assessment of socio‐economic considerations. This paper contributes to the ongoing policy dialogue by discussing issues related to socio‐economic assessment including scope, timing, inclusion modalities, methods, decision‐making rules and standards, and the integration of socio‐economic assessments in biosafety and/or biotechnology approval processes. This paper also discusses the implications of such inclusion for technology flows and public and private sector R&D. If inclusion is not done properly, it may negatively impact technology flows especially from the public sector and render an unworkable biosafety system.
ISSN:1541-132X
1541-1338
1541-1338
DOI:10.1111/j.1541-1338.2011.00488.x